

Pituitary Suppressive Agents, LHRH - Pennsylvania Prior Authorization Request Form

Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826.

This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Mem	Prescriber Information							
Member Name:			Provider Name:					
Member ID:			NPI #: Specialty:			<i>/</i> :		
Date Of Birth:	Office Phone:							
Street Address:	Office Fax:							
City:	State:	ZIP Code:	Office Street Address:					
Phone:	Allergies	::	City:	State: ZIP Code:				
Is the requested medication: New or Continuation of Therapy? If continuation, list start date: Is this patient currently hospitalized? Yes No If recently discharged, list discharge date: Is this member pregnant? Yes No If yes, what is this member's due date?								
is this member pregna				•				
Medication:		Medicatio	on Information		Strength)·		
Directions for use:					Quantity:			
					Luaminy.			
Medication Administered	I: ☐ Self-Admin	, , , , , , , , , , , , , , , , , , ,						
		Clinica	Information					
What is the patient's diagnosis for the medication being requested?								
ICD-10 Code(s):								
Are there any supporting laboratory or test results related to the patient's diagnosis? (Please specify or provide documentation)								
	Prev	ious Medication	Trials / Contraindic	ation	S			
Please refer to the patient's PDL at www.uhcprovider.com for a list of preferred alternatives								
What medication(s) does the patient have a history of failure to? (Please specify ALL medication(s)/strengths tried, directions, length of trial, and reason for discontinuation of each medication)								
What medication(s) does the patient have a contraindication or intolerance to? (Please specify ALL medication(s) with the associated contraindication to or specific issues resulting in intolerance to each medication)								
	Additio	nal information that	may be important for th	vie rov	iow			
Additional information that may be important for this review								



Pituitary Suppressive Agents, LHRH - Pennsylvania Prior Authorization Request Form

Date: _____

Member First name:		Member Last name:	Member DOB:				
Clinical and Drug Specific Information							
ALL REQUESTS							
□ Yes □ No	Does the patient have one of the following diagnoses? (If yes, check which applies) □ Central precocious puberty □ Management of heavy menstrual bleeding associated with □ Endometriosis □ uterine leiomyomas (fibroids) in premenopausal women □ Gender dysphoria □ Preservation of ovarian function						
□ Yes □ No	Does the patient have a history of contraindication to the prescribed medication?						
□ Yes □ No	If the requested medication is non-preferred, does the patient have history of therapeutic failure, contraindication, or intolerance of the preferred Pituitary Suppressive Agents, LHRH (luteinizing hormone-releasing hormone) approved or medically accepted for the patient's indication? (If yes, complete "Previous Medication Trials/Contraindications" section on first page)						
□ Yes □ No	If the request is for elagolix- or relugolix-containing agent, does the patient have a history of depression and/or suicidal thoughts or behaviors or is currently receiving treatment for depression and/or suicidal thoughts or behavior?						
□ Yes □ No	If yes to the above question, has the patient had a behavioral health assessment prior to use?						
□ Not applicable CENTRAL PRECOCIOUS PUBERTY							
□ Yes □ No	<u> </u>	· · · · · · · · · · · · · · · · · · ·					
□ Yes □ No	was the onset of second	ary sexual characteristics earlier than 8	3 years in females or 9 years in males?				
ENDOMETRIOSIS							
□ Yes □ No	Does the patient have one of the following? (If yes, check which applies) □ A diagnosis of endometriosis confirmed by laparoscopy □ A diagnosis of endometriosis supported by chart documentation of an adequate work-up that includes the clinical rationale for the diagnosis						
□ Yes □ No	Does the patient have history of any of the following? (If yes, check which applies & complete "Previous Medication Trials/Contraindications" section on first page) □ Therapeutic failure, contraindication, or intolerance of non-steroidal anti-inflammatory drugs □ Therapeutic failure (based on a 3-month trial), contraindication, or intolerance of oral contraceptives						
□ Yes □ No	Is the requested medicat	ion prescribed in consultation with a gy	/necologist?				
		GENDER DYSPHORIA - ADOLESCENT					
□ Yes □ No	Is the requested medication prescribed by or in consultation with a pediatric endocrinologist, adolescent medicine specialist, or medical provider with experience and-or training in transgender medicine?						
□ Yes □ No	Is the requested medication prescribed in a manner consistent with the current World Professional Association for Transgender Health standards of care for the health of transsexual, transgender, and gender nonconforming people?						
GENDER DYSPHORIA - ADULT							
□ Yes □ No	Is the requested medication prescribed by or in consultation with an endocrinologist or medical provider with experience and-or training in transgender medicine?						
□ Yes □ No	Is the requested medicat	ion prescribed in a manner consistent v	with current medical literature?				
MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN – ORIAHNN / MYFEMBREE							
□ Yes □ No	Does the patient have a history of therapeutic failure (based on a 3-month trial), contraindication, or intolerance of contraceptives? (If yes, complete "Previous Medication Trials/Contraindications" section on first page)						
PRESERVATION OF OVARIAN FUNCTION							
□ Yes □ No		ancer treatment that is associated with nensive Cancer Network) guidelines or					

Physician Signature:



Pituitary Suppressive Agents, LHRH - Pennsylvania Prior Authorization Request Form

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.